Fabry disease: Updates from the 15th Annual WorldSymposium
Cost: FreeView Offer chevron_right
Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels.
After completing Fabry disease: Updates from the 15th Annual WorldSymposium, physicians will better be able to:
- Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material presented at the 15th Annual WORLDSymposium
- Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
- Describe emerging therapies for Fabry disease based on research presented at the 15th Annual WORLDSymposium
- Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research presented at the 15th Annual WORLDSymposium
Target Audience: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.